Microneedle Biosensors Show Potential for Real-Time, Minimally Invasive Diagnostics
Key Points
- Microneedle biosensors detect biomarkers through interstitial fluid without conventional blood draws, with applications in diabetes, cancer, neurological disorders, and kidney disease.
- A pediatric glucose study showed microneedle measurements closely tracked finger-prick and venous results, with less pain reported by participants.
- Skin irritation, infection risk, and fabrication improvements remain barriers before broader clinical adoption.
Microneedle-based biosensors could offer a less invasive approach to continuous health monitoring, with emerging applications in diabetes, cancer, neurological disorders, and kidney disease, according to a review published in Discover Pharmaceutical Sciences.
Researchers Sudhanshu Kalantri, Anuj N. Nahata, and Nandan Godani examined advances in microneedle design, manufacturing, biosensor integration, and wearable power systems, highlighting the technology’s potential to detect biomarkers through interstitial fluid without conventional blood draws.
The review covers five microneedle designs: solid, hollow, dissolving, coated, and hydrogel-based. Depending on their construction, these devices can create temporary pathways through the skin, deliver medications, or collect interstitial fluid for analysis. Imaging studies cited by the authors indicate that approximately 25% of microchannels reseal within 20 minutes, with the skin barrier generally restored within six hours.
Integrated biosensors use electrochemical, optical, and other detection methods to measure specific biological markers. Researchers are also exploring self-powered systems that harvest energy from body movement, temperature differences, and biochemical reactions, potentially reducing reliance on conventional batteries.
Clinical and preclinical applications highlighted in the review include glucose monitoring in diabetes, detection of cancer-associated biomarkers, and levodopa monitoring for Parkinson’s disease. In one pediatric study involving 15 participants, microneedle-based glucose measurements closely tracked results from conventional finger-prick and venous sampling, while participants reported less pain and apprehension.
Despite the progress, challenges remain before broader clinical adoption. Potential concerns include skin irritation, inflammation, nerve stimulation, and infection risks associated with device insertion and manufacturing. The authors also identify the need for continued improvements in device design, fabrication, and biosensor performance.
Overall, the review points to microneedle biosensors as a developing platform that could combine drug delivery and real-time diagnostic monitoring in compact wearable devices.
Total Page Views: 8
